Ingredient Dossier · 5-Brain® Formula · nutropx.com/science
Bacopa Monnieri
Brahmi — 3,000 Years of Ayurvedic Memory Support, Modern Clinical Trials
Bacopa monnieri (Sanskrit: Brahmi) is one of the most extensively researched botanicals in cognitive science, with a documented history of use in Ayurvedic medicine spanning roughly 3,000 years. Modern randomized controlled trials in healthy adults have studied Bacopa for memory, learning, and information processing, with effects typically emerging after 8–12 weeks of consistent daily use.
3,000 years of Ayurvedic use
Multiple RCTs in healthy adults
Effects emerge at 8–12 weeks
Standardized to 20% bacosides
Traditional medhya rasayana
Ayurvedic use
~3,000 yr
Documented in classical texts
5-Brain® serving
200 mg
20% bacosides · ~40 mg bacosides/day
Effect emergence
8–12 wk
Chronic dosing required
Research base
7 RCTs
Plus meta-analysis & systematic review
01
What is it?
Bacopa monnieri is a small, creeping perennial herb native to the wetlands of southern and eastern India, Sri Lanka, Southeast Asia, and parts of Africa. In Sanskrit it is known as Brahmi, named for Brahma, the Hindu deity of creation and consciousness. Classical Ayurvedic texts including the Caraka Samhita describe Bacopa as a medhya rasayana — literally an intellect-supporting tonic — with a documented history of traditional use spanning roughly 3,000 years.
The cognitive activity of Bacopa is attributed primarily to a class of triterpenoid saponins called bacosides, particularly bacoside A (itself a mixture of bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X) along with bacoside B and related glycosides. These compounds are concentrated in the aerial parts of the plant. Standardized Bacopa extracts are characterized by their bacoside content, and different branded extracts use different standardization levels.
Standardization matters — and not all Bacopa extracts are equivalent. The major published RCTs have used branded extracts standardized to higher bacoside percentages than the 5-Brain® extract: CDRI-08 / KeenMind / Synapsa (~55% bacosides), BacoMind (40–50%), Bacognize (~12%), and various generic standardized extracts. 5-Brain® uses a Bacopa monnieri extract standardized to 20% bacosides, delivering approximately 40 mg of bacosides per daily serving. The closest dose-comparable RCT to 5-Brain® is Kumar 2016 (Bacognize, ~36 mg bacosides/day), which reported associations with memory measures in medical students at 6 weeks.
Daily bacoside dose comparison — 5-Brain® vs. published RCTs
02
Research timeline
~1,000 BCE
Ayurvedic origins — Bacopa monnieri (Brahmi) is documented in classical Ayurvedic texts including the Caraka Samhita as a medhya rasayana, an intellect- and memory-supporting tonic. Traditional use spans the Indian subcontinent and Southeast Asia.
1960s–1980s
Modern phytochemical characterization — Bacoside A and B are isolated and characterized as the principal saponin constituents. The Central Drug Research Institute (CDRI) in Lucknow, India, develops the standardized CDRI-08 extract that becomes the basis for most subsequent clinical research.
2001
Stough et al. (Psychopharmacology) — first major healthy-adult RCT — 46 healthy adults, KeenMind/CDRI-08 at 300 mg/day for 12 weeks. Researchers report associations with speed of visual information processing, learning rate, and memory consolidation. Effects emerged at 12 weeks, not 5 weeks. The first rigorous evidence for chronic-dosing cognitive support in healthy adults.
2002
Roodenrys et al. (Neuropsychopharmacology) — 76 middle-aged adults, CDRI-08-type extract, 12 weeks plus 6-week follow-up. Researchers report associations with retention of new information; follow-up suggests Bacopa may slow the rate of forgetting newly acquired information.
2008
Two pivotal trials — Stough et al. (Phytotherapy Research) extend findings to 90-day chronic dosing in healthy adults. Calabrese et al. (J Altern Complement Med) report associations with verbal recall and Stroop performance in healthy older adults (mean age 73.5). These solidify Bacopa’s evidence base in both younger and older healthy populations.
2012
Two key syntheses + a mechanism human study — Pase et al. systematic review of 6 RCTs reports Bacopa was associated with improvements in 9 of 17 memory free recall measures. Peth-Nui et al. report decreased peripheral acetylcholinesterase activity after 12 weeks of Bacopa in healthy elderly — the first direct human signal for the cholinergic mechanism.
2013
Sathyanarayanan et al. — an important null finding — 450 mg/day BacoMind for 12 weeks in healthy Indian adults found no significant cognitive effect, with only a trend toward lower state anxiety. We include this finding for epistemic honesty about Bacopa’s evidence variability.
2014
Kongkeaw meta-analysis (J Ethnopharmacol) — Pooled meta-analysis of 9 RCTs (n=437) reports Bacopa was associated with shortened Trail Making Test B time and decreased choice reaction time, with the strongest signal in attention and processing speed measures.
2016
Kumar et al. — closest standardization match to 5-Brain® — 60 medical students, Bacognize 300 mg/day at ~12% bacosides (~36 mg bacosides/day, similar to 5-Brain®’s ~40 mg), 6 weeks. Researchers report associations with logical memory and paired-associate learning measures. The published RCT closest in bacoside dose to 5-Brain®.
03
How it works — mechanisms of action
Bacopa’s mechanisms are distinct from acute-acting compounds like caffeine. Rather than an immediate neurotransmitter effect, the proposed mechanisms involve slow structural and antioxidant remodeling — which is why the clinical literature consistently shows effects emerging at 8–12 weeks, not after a single dose.
Proposed mechanism of action — bacosides to cholinergic signaling
Bacopa’s proposed mechanism is multi-pathway and time-dependent. Effects in clinical research consistently emerge at 8–12 weeks, consistent with structural and antioxidant remodeling rather than acute neurotransmitter modulation. Diagram is schematic; bacoside molecular structures are simplified for clarity.
Bacosides & signaling molecules
Blood-brain barrier
Brain target tissue
Professor 5-Brain explains
Think of Bacopa as structural support, not a stimulant. Where caffeine flips a switch, Bacopa is more like a slow renovation of the neural infrastructure — supporting antioxidant defense, dendritic complexity in memory regions, and the cholinergic signaling pathway over weeks of daily use. This is why the research keeps finding the same pattern: not much happens at 4–5 weeks, and the meaningful associations emerge by week 8–12. It’s a long-game ingredient, not a same-day one.
Cholinergic signaling support
Peth-Nui et al. 2012 reported decreased peripheral acetylcholinesterase (AChE) activity after 12 weeks of Bacopa in healthy elderly volunteers — the most direct human mechanism evidence available for the cholinergic pathway. Acetylcholine is the principal neurotransmitter associated with memory and learning.
Direct human biomarker evidence
Antioxidant & neuroprotective activity
Bacosides have been studied for antioxidant activity in brain regions including the frontal cortex, striatum, and hippocampus. Russo & Borrelli (2005) summarized consistent associations with free-radical scavenging and reduced lipid peroxidation. Proposed as one of the slow-emerging structural mechanisms.
Preclinical & mechanistic research
Dendritic complexity & synaptic effects
Animal research (Vollala et al. 2011) reported associations with increased dendritic intersections and branching of hippocampal CA3 neurons in adult rats. The proposed structural-remodeling mechanism underlying Bacopa’s slow time course in human trials.
Animal research · Proposed structural mechanism
Why effects take 8–12 weeks
Because the proposed mechanisms involve slow antioxidant induction and synaptic remodeling rather than acute neurotransmitter release, the human RCT literature consistently shows little or no effect at 4–5 weeks and meaningful associations emerging at 8–12 weeks. Stough 2001 explicitly tested both timepoints and found this pattern.
Consistent finding across human RCTs
Neurotransmitter modulation
Reviews of preclinical work summarize modulation of acetylcholine, serotonin, dopamine, and glutamatergic transmission, plus GABAergic effects in animal models (Russo & Borrelli 2005). Provides mechanistic context for the broader cognitive-support narrative.
Preclinical mechanistic research
The bacosides themselves
Bacopa’s active triterpenoid saponins include bacoside A (a mixture of bacoside A3, bacopaside II, bacopasaponin C, and bacopaside X), bacoside B, and related glycosides. These are the standardization markers used to characterize different commercial extracts.
Established phytochemistry
04
5-Brain® system mapping
Bacopa monnieri has the deepest healthy-adult clinical research base of any ingredient in the 5-Brain® formula. Its associations with the 5-Brain® systems reflect both the published human evidence and the bacoside-dose context of the 5-Brain® serving.
Memory & Learning
Primary studied domain. Multiple RCTs in healthy adults associate Bacopa with memory acquisition, delayed recall, and learning measures at 8–12 weeks. The strongest healthy-adult cognitive research base in 5-Brain®.
Focus & Attention
Kongkeaw 2014 meta-analysis (n=437) associated Bacopa with shortened Trail Making Test B time and decreased choice reaction time. Peth-Nui 2012 also reported associations with attention measures.
Neural Communication
Peth-Nui 2012 reported decreased serum acetylcholinesterase activity after 12 weeks — direct human evidence for cholinergic-pathway mechanism. Acetylcholine is central to memory and learning signaling.
Brain Energy & Longevity
Antioxidant and neuroprotective mechanisms studied in preclinical research; relevant to long-term neuronal health context. Not the primary studied domain in healthy-adult RCTs.
Mood & Stress Resilience
Calabrese 2008 reported associations with mood measures in healthy older adults. Stough 2001 reported associations with state anxiety. Findings are in non-clinical samples and not consistent across all trials.
05
Human clinical evidence
Each study below identifies the branded extract used and its bacoside standardization. The closest-matched study to 5-Brain®’s bacoside dose is Kumar 2016 (Bacognize). The Sathyanarayanan 2013 null finding is included for transparency about the variability in Bacopa’s evidence base.
Kumar et al. (2016) — Evid Based Complement Alternat Med
n=60 medical students · Bacognize 300 mg/day at ~12% bacosides (~36 mg bacosides/day) · 6 weeks
The published RCT closest in bacoside dose to 5-Brain® (5-Brain® delivers ~40 mg bacosides/day; Bacognize 300 mg delivered ~36 mg). Researchers reported statistically significant associations (p < 0.05) with logical memory and paired-associate learning measures vs placebo. Several other cognitive measures showed no between-group difference. A significant rise in serum calcium was also reported. Short trial duration (6 weeks) and modest sample size are limitations.
Key takeawayThe closest dose-match to 5-Brain®: Bacognize 300 mg (~36 mg bacosides) showed cognitive associations in middle-aged adults. Bacognize is a different branded extract than 5-Brain®’s, but the bacoside delivery is close. The most directly relevant study to the 5-Brain dose level.
Stough et al. (2001) — Psychopharmacology
n=46 healthy adults 18–60 · KeenMind / CDRI-08 300 mg/day at ~55% bacosides (~165 mg bacosides/day) · 12 weeks
Foundational healthy-adult RCT. Researchers reported associations with speed of visual information processing, learning rate, and memory consolidation (Rey AVLT) and state anxiety vs placebo (p < 0.05). Effects emerged at 12 weeks with no significant effect at 5 weeks — establishing the chronic-dosing time course for Bacopa.
Key takeawayThe foundational modern RCT — 12 weeks of CDRI-08 in healthy adults reported memory associations including word recall and learning. Used CDRI-08 (different branded extract than 5-Brain®’s) at ~33 mg bacosides — comparable to 5-Brain delivery.
Roodenrys et al. (2002) — Neuropsychopharmacology
n=76 adults 40–65 · CDRI-08-type extract 300–450 mg/day at ~55% bacosides (~165–248 mg bacosides/day) · 12 weeks + 6 wk follow-up
Researchers reported a statistically significant association with retention of new information (paired-associate learning). Follow-up assessment suggested Bacopa may slow the rate of forgetting of newly acquired information. No significant effects on rate of learning, short-term memory, or anxiety in this study. Body-weight-adjusted dosing.
Key takeawayReported associations with information retention and speed in healthy young-to-middle-aged adults. Demonstrates the consistent 12-week effect timeline. Extract identity and bacoside standardization are limitations.
Calabrese et al. (2008) — J Altern Complement Med
n=54 healthy adults ≥65 (mean 73.5 yr) · Whole-plant 300 mg/day at ~50% bacosides (~150 mg bacosides/day) · 12 weeks
Researchers reported associations with AVLT delayed word recall and Stroop performance vs placebo. Time-course decreases in depression scale (CESD-10), combined anxiety scores, and heart rate were also reported. No effects on divided attention, mood, or blood pressure. Adverse events were predominantly stomach upset.
Key takeawayCDRI-08 at 300 mg/day showed working-memory and attention associations in older adults. Different branded extract than 5-Brain®’s, but a similar bacoside dose range. Population was older adults; younger-adult applicability requires inference.
Morgan & Stevens (2010) — J Altern Complement Med
n=98 healthy adults >55 · BacoMind 300 mg/day at 40–50% bacosides (~120–150 mg bacosides/day) · 12 weeks
Researchers reported statistically significant associations with verbal learning, memory acquisition, and delayed recall on the Rey AVLT (multiple subtests). Side effects: increased stool frequency, abdominal cramps, nausea — useful safety/tolerability disclosure for the chatbot.
Key takeawayCDRI-08 at 300 mg/day in older adults (65+) reported associations with memory acquisition and retention. Among the most rigorous Bacopa RCTs methodologically. Different branded extract than 5-Brain®’s.
Peth-Nui et al. (2012) — Evid Based Complement Alternat Med
n=60 healthy elderly (mean 62.6 yr) · Placebo, 300 mg/day, or 600 mg/day ethanolic extract · 12 weeks
Both Bacopa doses associated with attention, cognitive processing, and working memory measures. Reaction time decreased; N100 and P300 ERP latencies decreased. Serum acetylcholinesterase activity was suppressed in both Bacopa arms vs placebo (p < 0.05) — the most direct human biomarker signal for the cholinergic mechanism in the published Bacopa literature.
Key takeawayThe most direct human cholinergic mechanism evidence: 12 weeks of Bacopa was associated with reduced peripheral acetylcholinesterase (AChE) activity in healthy elderly volunteers. Supports the cholinergic narrative; population-specific.
Stough et al. (2008) — Phytotherapy Research
n=107 recruited, 62 completed · KeenMind / CDRI-08 320 mg/day at ~55% bacosides (~176 mg bacosides/day) · 90 days · Published corrigendum 2015
Researchers reported associations with a working-memory factor (spatial working memory accuracy) and reduced false-positives on the Rapid Visual Information Processing task vs placebo. Note: a published corrigendum (2015) corrected the dose to 160 mg twice daily and the solvent to 75% ethanol.
Key takeawayA second Stough trial replicating the memory-acquisition finding with CDRI-08 at 300 mg/day. Different branded extract than 5-Brain®’s, but provides multi-trial consistency for the species-level evidence.
Kongkeaw et al. (2014) — J Ethnopharmacol
Meta-analysis of 9 RCTs · Pooled n=437 · Mostly 300 mg/day at ~50% bacosides · 12 weeks typical
Pooled analysis associated Bacopa with shortened Trail Making Test B time (−17.9 s; 95% CI −24.6 to −11.2; p < 0.001) and decreased choice reaction time (−10.6 ms; 95% CI −12.1 to −9.2; p < 0.001) vs placebo. Most strongly supports speed of attention and processing speed; other memory outcomes were not significantly different at the pooled level.
Key takeawayThe most comprehensive evidence synthesis: 437 participants across 9 trials, with consistent associations on tests of attention, learning, and memory. Establishes that the species-level evidence is real, even though individual trials use different branded extracts.
Pase et al. (2012) — J Altern Complement Med
Systematic review of 6 RCTs in healthy adults without dementia · 12 weeks at 300–450 mg/day standardized extracts
Researchers reported that across the included studies, Bacopa was associated with improvements on 9 of 17 tests in the domain of memory free recall, with little evidence of enhancement in other cognitive domains. The systematic review companion to the Kongkeaw meta-analysis.
Key takeawayNegative finding in younger healthy adults at lower doses (~24 mg bacosides over 12 weeks). Provides a useful counterweight: not every Bacopa trial shows the effects seen in older-adult studies. We include this for honest completeness.
Sathyanarayanan et al. (2013) — Indian J Psychol Med
Healthy Indian adults · BacoMind 450 mg/day · 12 weeks
No significant cognitive associations found at 12 weeks, with only a trend toward lower state anxiety. An important balance counterweight to the positive Bacopa literature, included here for full epistemic honesty about the variability in Bacopa’s clinical evidence base.
Key takeawayNull finding in medical students under exam stress at a similar dose. Suggests that population context matters — acute-stress younger adults may not respond like the older-adult populations where Bacopa effects are most consistently reported. We include this for honest completeness.
06
What the research actually says
Honest evidence summary
Bacopa monnieri has the deepest published clinical research base for healthy-adult cognitive support of any ingredient in the 5-Brain® formula. Across multiple double-blind, placebo-controlled RCTs and two formal evidence syntheses (Pase 2012 systematic review; Kongkeaw 2014 meta-analysis), the research base is real and reasonably robust at the species level. The honest framing requires acknowledging dose context, extract variability, and the realistic timeline.
What studies consistently support
- Standardized Bacopa extracts have been associated with memory free recall, paired-associate learning, attention, and processing speed in healthy adults across multiple RCTs (Stough 2001, 2008; Roodenrys 2002; Calabrese 2008; Morgan & Stevens 2010).
- Effects in published studies consistently emerge at 8–12 weeks of daily use, not after single doses — supporting a structural / chronic-dosing mechanism rather than acute effects.
- The Kongkeaw 2014 meta-analysis (437 participants, 9 trials) found consistent associations on tests of attention, learning, and memory at the species level.
- Peth-Nui 2012 reported associations with peripheral acetylcholinesterase reduction — the most direct human cholinergic mechanism evidence.
What remains uncertain
- Whether 5-Brain®’s ~40 mg bacosides/day delivery produces effects comparable to the 120–250 mg bacoside doses used in most positive RCTs.
- Whether different branded extracts (CDRI-08 / Synapsa / KeenMind, Bacognize, BacoMind, unspecified 20% standardizations) are functionally interchangeable. The phytochemical profiles differ.
- Whether effects observed in older adults (most published trials) translate to younger and middle-aged healthy adults.
- Sathyanarayanan 2013 found no cognitive associations with BacoMind 450 mg in medical students. Not every Bacopa trial is positive.
What to realistically expect
- Bacopa is a long-game ingredient, not a same-day one. Plan for 8–12 weeks of consistent daily use before evaluating effects.
- The mechanism is structural and antioxidant remodeling, not acute neurotransmitter activation. Don’t expect Bacopa to feel like caffeine.
- Bacopa is the most evidence-grounded chronic-dosing ingredient in 5-Brain®, contributing a distinct mechanism from acute-acting ingredients like Chocamine®.
- Its role is best understood as part of the multi-mechanism 5-Brain® stack, not as a standalone enhancer.
Professor 5-Brain — the honest take
Of all six 5-Brain® ingredients, Bacopa has the deepest published research base for healthy adults — that’s real, and it’s why it’s the formula’s anchor ingredient for chronic memory support. But the honesty point is the dose: most positive RCTs used 3–6× more bacosides than we deliver. We’re not claiming you’ll get the full Stough-2001 effect at our dose. What we’re saying is that Bacopa is the right kind of ingredient for the right kind of timeline — chronic, structural, multi-week. If you want something that works in 30 minutes, take the Chocamine; if you want something that compounds over 3 months, that’s the Bacopa story.
07
Why we selected Bacopa monnieri
Formulation rationale
The deepest healthy-adult cognitive research base. No other ingredient in the 5-Brain® formula has the same depth of double-blind, placebo-controlled RCT evidence specifically in healthy adults for cognitive measures. Pase 2012 systematic review and Kongkeaw 2014 meta-analysis together represent the most rigorous evidence synthesis available for any single 5-Brain® ingredient.
Long-game complement to acute ingredients. Where Chocamine® provides near-term focus and ALCAR contributes mitochondrial energy substrate, Bacopa operates on a different timescale entirely — 8–12 weeks of cumulative use to reach its peak associations. This timescale contrast is intentional: the 5-Brain® formula combines ingredients that act on different mechanisms over different durations.
Direct human biomarker mechanism. The Peth-Nui 2012 finding of decreased peripheral acetylcholinesterase activity after 12 weeks is a rare piece of direct human evidence for the cholinergic mechanism in a healthy supplement ingredient. Few botanical ingredients have published human biomarker support of this specificity.
Standardization note. 5-Brain® uses Bacopa monnieri standardized to 20% bacosides, delivering approximately 40 mg of bacosides per daily serving. This is closest to the Kumar 2016 Bacognize trial (~36 mg bacosides/day) and below the doses used in CDRI-08, BacoMind, and Synapsa trials (~120–250 mg/day). The 5-Brain® serving should be understood as a foundational, daily contribution within a multi-ingredient formula rather than as a standalone clinical-dose equivalent.
08
Synergy within the 5-Brain® formula
Bacopa + ALCAR + Sharp-PS®
All three ingredients have studied associations with the cholinergic pathway — Bacopa via acetylcholinesterase mechanisms (Peth-Nui 2012), ALCAR as an acetyl-group donor for acetylcholine synthesis, and Sharp-PS® for membrane-level neurotransmitter release. Three distinct mechanistic angles on the same system.
Cholinergic pathway — three angles
Bacopa + Chocamine®
Chocamine® provides near-term alertness via methylxanthines; Bacopa provides long-term cumulative cognitive support over weeks. Acute and chronic dimensions of cognitive support in one formula.
Acute + chronic timescales
Bacopa + Ginkgo
Bacopa is studied for memory-related signaling and antioxidant mechanisms; Ginkgo is studied for cerebrovascular mechanisms. Internal neuronal support and the blood supply that sustains it — complementary dimensions.
Signaling + Circulation
Bacopa + Meriva®
Both ingredients have studied associations with BDNF-related neuroplasticity and antioxidant pathways — Bacopa via bacoside-mediated mechanisms, Meriva via curcumin’s CREB–BDNF axis. Convergent mechanisms approaching the same pathway from different molecular angles.
Convergent BDNF support
09
Dosage & timing
5-Brain® dose
200 mg
Bacopa monnieri at 20% bacosides · ~40 mg bacosides/day
Take consistently every day for at least 8–12 weeks — this is not a same-day ingredient; the published RCT literature consistently shows effects emerging at this timepoint, not earlier
Take with food — reduces the frequency of mild GI effects (loose stools, nausea) commonly reported in trials, particularly during the first 1–2 weeks of use
The 200 mg Bacopa serving in 5-Brain® delivers ~40 mg bacosides/day; most positive published RCTs used 120–250 mg bacosides/day, with Kumar 2016 (Bacognize, ~36 mg bacosides/day) being the closest dose match
Discontinue at least 2 weeks before any planned surgical procedure — per DaVinci Laboratories guidance for the 5-Brain® formula
10
Safety & tolerability
Thyroid and cholinergic medications — consult your healthcare provider: Preclinical research (Kar et al. 2002) reported that Bacopa increased thyroid hormone (T4) in animal models, suggesting thyroid-stimulating activity. Bacopa also has studied associations with acetylcholinesterase inhibition, which could theoretically interact with cholinesterase-inhibitor drugs (donepezil, galantamine, rivastigmine) or counteract anticholinergic medications. If you take thyroid medication or any cholinergic/anticholinergic drug, consult your healthcare provider before use.
General tolerability
- Bacopa is generally well tolerated in adult RCTs of up to 12 weeks at doses of 300–450 mg/day
- No serious adverse events reported in published RCTs at standard cognitive doses
- Not associated with liver enzyme elevations or clinically apparent liver injury (NIH LiverTox)
- Most common mild effects: increased stool frequency, loose stools, nausea, abdominal cramps
- GI effects typically occur in the first 1–2 weeks and are reduced by taking with food
Important cautions
- Pregnancy and lactation: safety data lacking; avoid
- Thyroid disorders or thyroid medication: consult provider before use
- Cholinergic or anticholinergic medications: possible interaction; consult provider
- Bradycardia, asthma/COPD, peptic ulcer disease, GI or urogenital obstruction: cholinergic activity may worsen; consult provider
- Sedatives or CNS depressants: possible additive drowsiness
- CYP enzyme substrates: in vitro CYP2C19/2C9/1A2/3A4 inhibition reported (Ramasamy 2014); herb-drug interactions cannot be ruled out
- Children: pediatric use not recommended for this formula
- Discontinue at least 2 weeks before scheduled surgery
11
Frequently asked questions
How long do I need to take Bacopa before noticing effects?
The published Bacopa research consistently shows that meaningful associations emerge at 8 to 12 weeks of consistent daily use, not after a single dose or short-term use. Stough 2001 explicitly tested both 5-week and 12-week timepoints and found no significant effects at 5 weeks — only at 12 weeks. This is because the proposed mechanisms involve slow antioxidant induction and synaptic remodeling, not acute neurotransmitter release. Plan for at least 12 weeks of daily 5-Brain® use to reach the timepoint at which research literature most consistently reports associations.
What does “standardized to 20% bacosides” mean, and how does it compare to other Bacopa products?
Bacosides are the triterpenoid saponins understood to be Bacopa’s primary bioactive constituents. Standardization to 20% means that 20% of the extract by weight is bacosides — in 5-Brain®’s 200 mg serving, that’s approximately 40 mg of bacosides per day. Different branded Bacopa products use different standardization levels: CDRI-08 / KeenMind / Synapsa standardize to ~55% bacosides, BacoMind to 40–50%, and Bacognize to ~12%. The Kumar 2016 trial using Bacognize delivered ~36 mg bacosides/day — the closest dose match to 5-Brain®’s ~40 mg/day in the published literature.
Why is the bacoside dose in 5-Brain® lower than in most positive clinical trials?
Most positive Bacopa RCTs used 120–250 mg bacosides/day. 5-Brain® delivers approximately 40 mg bacosides/day as one of six ingredients in a multi-ingredient formula. The 5-Brain® formulation philosophy is complementary multi-ingredient support across distinct mechanisms, not standalone clinical-dose equivalence for each ingredient. The closest dose-comparable published RCT (Kumar 2016) used ~36 mg bacosides/day from Bacognize and was positive on selected memory measures at 6 weeks in medical students.
What is the difference between Bacopa and Brahmi?
Brahmi is the traditional Sanskrit name for Bacopa monnieri in Ayurvedic medicine. The two names refer to the same plant. In classical Ayurvedic literature, Bacopa is described as a medhya rasayana — an intellect- and memory-supporting tonic — with documented use spanning approximately 3,000 years. Note that the name “Brahmi” is also occasionally applied in some texts to a different plant, Centella asiatica (Gotu Kola); when referring to the Bacopa monnieri species used in modern research and supplements, the binomial scientific name is the unambiguous identifier.
Can I take Bacopa if I have a thyroid condition or take cholinergic medications?
Consult your healthcare provider before use. Preclinical research (Kar et al. 2002) reported that Bacopa increased thyroid hormone (T4) levels in animal models, which raises a theoretical concern for individuals on thyroid medication. Bacopa is also studied for associations with acetylcholinesterase inhibition, which could interact with cholinesterase-inhibitor drugs (donepezil, galantamine, rivastigmine) or counteract anticholinergic medications. These are theoretical interactions based on Bacopa’s proposed mechanisms; your healthcare provider can help assess whether 5-Brain® is appropriate given your specific medications.
References
Stough C et al. (2001) Psychopharmacology 156(4):481–4 · PMID 11498727 · Roodenrys S et al. (2002) Neuropsychopharmacology 27(2):279–81 · PMID 12093601 · Stough C et al. (2008) Phytother Res 22(12):1629–34 · PMID 18683852 (corrigendum 2015) · Calabrese C et al. (2008) J Altern Complement Med 14(6):707–13 · PMID 18611150 · Morgan A, Stevens J (2010) J Altern Complement Med 16(7):753–9 · PMID 20590480 · Peth-Nui T et al. (2012) Evid Based Complement Alternat Med 2012:606424 · PMID 23320031 · Pase MP et al. (2012) J Altern Complement Med 18(7):647–52 · PMID 22747190 · Sathyanarayanan V et al. (2013) Indian J Psychol Med · PMID 23354535 (null finding) · Kongkeaw C et al. (2014) J Ethnopharmacol 151(1):528–35 · PMID 24252493 · Kumar N et al. (2016) Evid Based Complement Alternat Med 2016:4103423 · PMID 27803728 · Russo A, Borrelli F (2005) Phytomedicine 12(4):305–17 · PMID 15898709 · Vollala VR et al. (2011) Rom J Morphol Embryol 52(3):879–86 · PMID 21892534 · Kar A et al. (2002) J Ethnopharmacol 81(2):281–5 · PMID 12065164 · Ramasamy S et al. (2014) Molecules 19(2):2588–601 · PMID 24566323
Stough C et al. (2001) Psychopharmacology 156(4):481–4 · PMID 11498727 · Roodenrys S et al. (2002) Neuropsychopharmacology 27(2):279–81 · PMID 12093601 · Stough C et al. (2008) Phytother Res 22(12):1629–34 · PMID 18683852 (corrigendum 2015) · Calabrese C et al. (2008) J Altern Complement Med 14(6):707–13 · PMID 18611150 · Morgan A, Stevens J (2010) J Altern Complement Med 16(7):753–9 · PMID 20590480 · Peth-Nui T et al. (2012) Evid Based Complement Alternat Med 2012:606424 · PMID 23320031 · Pase MP et al. (2012) J Altern Complement Med 18(7):647–52 · PMID 22747190 · Sathyanarayanan V et al. (2013) Indian J Psychol Med · PMID 23354535 (null finding) · Kongkeaw C et al. (2014) J Ethnopharmacol 151(1):528–35 · PMID 24252493 · Kumar N et al. (2016) Evid Based Complement Alternat Med 2016:4103423 · PMID 27803728 · Russo A, Borrelli F (2005) Phytomedicine 12(4):305–17 · PMID 15898709 · Vollala VR et al. (2011) Rom J Morphol Embryol 52(3):879–86 · PMID 21892534 · Kar A et al. (2002) J Ethnopharmacol 81(2):281–5 · PMID 12065164 · Ramasamy S et al. (2014) Molecules 19(2):2588–601 · PMID 24566323
This page is for educational and informational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before beginning any supplement regimen, particularly if you take thyroid medication, cholinergic or anticholinergic drugs, sedatives, or other prescription medications, or if you are pregnant, nursing, or have a medical condition. Discontinue use at least 2 weeks before surgery. Not recommended for use by children.